Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.
Commentary|Articles|July 28, 2026
Beyond the trials: Pegcetacoplan slows GA progression in eyes with concurrent nAMD
Hasenin Al-khersan, MD, of the Retina Group of Florida, shares real-world RCA registry findings showing that pegcetacoplan significantly reduced both photoreceptor and RPE loss in eyes with GA.
Advertisement
Advertisement
Related to this article
Jayakrishna Ambati, MD, discusses phase 2 K8 results in GA, its inflammasome mechanism, and dosing designed for convenience.
Christopher J. Rapuano, MD, discusses emergency eye care access, retina advances and responsible AI use in ophthalmology.
Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.
Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME
Kiril Kiprovski, MD, of NYU Langone shares clinical clues and bedside tests for spotting Lambert-Eaton myasthenic syndrome.
Hunter Cherwek, MD, of Orbis discusses summit commitments, eye care workforce training, and AI in low-resource settings.
Technician-led screening catches hidden ocular surface disease before cataract surgery and helps decide when to delay surgery.
Advertisement
Advertisement